Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Sun Pharma Aims To Buy Controlling Stake In Israel’s Taro Under Merger Pact Options Clause

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's Sun Pharma said it will exercise an option to buy 12 percent of Israel-based Taro Pharma held by the founding Levitt family, which includes special voting shares that would give the Mumbai-based firm control to end a disputed merger agreement

You may also be interested in...



PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma

NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.

PharmAsia News Notable Notes: Citigroup Reiterates Buy On India’s Sun Pharma

NEW DELHI - Citigroup Global Markets reiterated its buy on Sun Pharma, India's largest drug company by market capitalization, saying a recent price dip related to a disputed merger attempt with Israel's Taro Pharma offers a "window of opportunity.

India’s Sun Pharma Claims Taro’s Proposed Sale Of Irish Plant Not Transparent

NEW DELHI - The spurned suitor of Taro Pharma has accused the Israel-based firm of favoring family in the proposed sale of an Irish manufacturing plant at Roscrea, Ireland, in an increasingly bitter battle following Taro's termination of a merger agreement earlier this month

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel